Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

@article{Wachtell2005AngiotensinIR,
  title={Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.},
  author={Kristian Wachtell and Mika Lehto and Eva Gerdts and Michael H. Olsen and Bj{\"o}rn Hornestam and Bj{\"o}rn Dahl{\"o}f and Hans Henning Windel{\o}v Ibsen and Stevo Julius and Sverre Erik Kjeldsen and Lars Lindholm and Markku S Nieminen and RichardB. Devereux},
  journal={Journal of the American College of Cardiology},
  year={2005},
  volume={45 5},
  pages={
          712-9
        }
}
OBJECTIVES This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF). BACKGROUND It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF. METHODS In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 315 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

Systolic left ventricular function improves more by beta - blockade than losartan : the LIFE study ( abstr )

  • K Wachtell, E Gerdts, V Palmieri
  • Am J Hypertens
  • 2003

( LIFE ) study

  • EJ Benjamin, RB D’Agostino, AJ Belanger, PA Wolf, D Levy
  • 2002

Similar Papers

Loading similar papers…